Robert Wesolowski, MD
College of Medicine
Breast Cancer ● Cancer ● Hypersensitivity ● Carcinoma, Hepatocellular ● Carcinoma ● Sarcoma ● Neutropenia ● Neoplasm Metastasis ● Stomach Cancer ● Prostatic Cancer
Robert Wesolowski, MD, is a principal investigator on numerous solid tumor phase I clinical trials in the Division of Medical Oncology at The Ohio State University and a member of the Translational Therapeutics Program at the OSUCCC – James. His research is focused on conducting early phase clinical trials testing novel and promising treatments with a focus on immunotherapy and breast cancer immunology.He has conducted many investigator-initiated trials, including a Pelotonia-supported study testing the effects of ibrutnib and nivolumab on levels and immunosuppressive function of circulating myeloid-derived suppressor cells (MDSC). He is also studying whether MDSC levels can be used as prognostic and predictive biomarkers. MDSC are important inhibitors of antitumor immune response and can be implicated in the resistance to immune checkpoint inhibitors. Dr. Wesolowski is also a member of the Solid Tumor Phase I Clinic, where he sees cancer patients who have an interest in or are currently participating in phase I clinical trials, and has grant support from the National Cancer Institute Additionally, he has co-authored multiple articles in such well-respected journals as Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Breast Cancer Research and Treatment, Therapeutic Advances in Medical Oncology, Investigational New Drugs, The Oncologist, Journal of National Comprehensive Cancer Network, OncoImmunology, Proceedings of the National Academy of Sciences of the United States of America, Cancer Immunology/Immunotherapy and Molecular and Cellular Endocrinology.
BA, Hunter College
New York, NY (USA)
MD, SUNY Downstate Medical Center
Brooklyn, NY (USA)